The Lancet Regional Health. Europe (Apr 2024)
Management of patients with rare adult solid cancers: objectives and evaluation of European reference networks (ERN) EURACAN
- Jean-Yves Blay,
- Paolo Casali,
- Isabelle Ray-Coquard,
- Michael J. Seckl,
- Jourik Gietema,
- Wouter W. de Herder,
- Martyn Caplin,
- Heinz-Josef Klümpen,
- Olivier Glehen,
- Lucjan Wyrwicz,
- Robin Peeters,
- Lisa Licitra,
- Nicolas Girard,
- Sophie Piperno-Neumann,
- Ellen Kapiteijn,
- Ahmed Idbaih,
- Enrico Franceschi,
- Annalisa Trama,
- Anna-Maria Frezza,
- Peter Hohenberger,
- Nadia Hindi,
- Javier Martin-Broto,
- Johanna Schell,
- Muriel Rogasik,
- Stephane Lejeune,
- Kathy Oliver,
- Francesco de Lorenzo,
- Ariane Weinman
Affiliations
- Jean-Yves Blay
- Department of Medical Oncology, Centre Leon Berard & Centre de Recherche en Cancérologie de Lyon (CRCL) & Université Claude Bernard Lyon 1, Lyon, France; Corresponding author.
- Paolo Casali
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
- Isabelle Ray-Coquard
- Department of Medical Oncology, Centre Leon Berard & Centre de Recherche en Cancérologie de Lyon (CRCL) & Université Claude Bernard Lyon 1, Lyon, France
- Michael J. Seckl
- Department of Medical Oncology, Imperial College Hospitals National Health Service (NHS) Trust (ICHNT), London, United Kingdom
- Jourik Gietema
- Department of Medical Oncology, University Medical Centre Groningen, Groningen, the Netherlands; University of Groningen Groningen, the Netherlands
- Wouter W. de Herder
- Department of Internal Medicine, Sector of Endocrinology, Erasmus MC and Erasmus MC Cancer Institute, Rotterdam, the Netherlands
- Martyn Caplin
- Royal Free London NHS Foundation Trust, London, United Kingdom
- Heinz-Josef Klümpen
- Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
- Olivier Glehen
- Department of Surgical Oncology, Centre Hospitalier Lyon Sud, Equipe CICLY & Université Claude Bernard Lyon 1, Lyon, France
- Lucjan Wyrwicz
- M Sklodowska Curie Memorial Cancer Centre, Warsaw, Poland
- Robin Peeters
- Department of Internal Medicine, Erasmus MC, Rotterdam, the Netherlands
- Lisa Licitra
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
- Nicolas Girard
- Department of Medical Oncology, Institut Curie, Paris, France
- Sophie Piperno-Neumann
- Department of Medical Oncology, Institut Curie, Paris, France
- Ellen Kapiteijn
- Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands
- Ahmed Idbaih
- Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau, ICM, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, Service de Neurologie 2-Mazarin, Paris, France
- Enrico Franceschi
- Azienda USL / IRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy
- Annalisa Trama
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
- Anna-Maria Frezza
- Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy
- Peter Hohenberger
- Div. of Surgical Oncology and Thoracic Surgery, Mannheim University Medical Centre, University of Heidelberg, Mannheim, Germany
- Nadia Hindi
- Fundación Jiménez Díaz University Hospital, Madrid, Spain; Spanish Group for Research on Sarcoma (GEIS), Spain
- Javier Martin-Broto
- Fundación Jiménez Díaz University Hospital, Madrid, Spain; Spanish Group for Research on Sarcoma (GEIS), Spain
- Johanna Schell
- EURACAN Unit Centre Léon Bérard, Lyon, France
- Muriel Rogasik
- EURACAN Unit Centre Léon Bérard, Lyon, France
- Stephane Lejeune
- European Organisation for Research and Treatment of Cancer (EORTC), Brussels, Belgium
- Kathy Oliver
- The International Brain Tumour Alliance (IBTA), Tadworth, United Kingdom
- Francesco de Lorenzo
- European Cancer Patient Coalition (ECPC), Belgium
- Ariane Weinman
- European Patient Organisation for Rare Diseases (EURORDIS-Rare Diseases Europe), Brussels, Belgium
- Journal volume & issue
-
Vol. 39
p. 100861
Abstract
Summary: About 500,000 patients with rare adult solid cancers (RASC) are diagnosed yearly in Europe. Delays and unequal quality of management impact negatively their survival. Since 2017, European reference networks (ERN) aim to improve the quality of care of patients with rare disease. The steering committee of EURACAN, including physicians, researchers and patients review here the previous actions, present objectives of the ERN EURACAN dedicated to RASC. EURACAN promoted management in reference centres, and equal implementation of excellence and innovation in Europe and developed 22 clinical practice guidelines (CPGs). Additionally, fourteen information brochures translated in 24 EU languages were developed in collaboration with patient advocacy groups (ePAGs) and seventeen training session were organized. Nevertheless, connections to national networks in the 26 participating countries (106 centres), simplification of cross-border healthcare, international multidisciplinary tumour boards, registries and monitoring of the quality of care are still required. In this Health Policy, evaluation criteria of the performances of the network and of health care providers are proposed.